Iproniazid
From Psychology Wiki
Community portal · Tasks to do · News · Help
Clinical · Educational · Ind&Org · Other fields · Professional · Transpersonal · World
Assessment |
Biopsychology |
Comparative |
Cognitive |
Developmental |
Language
Personality |
Philosophy |
Research Methods |
Social |
Statistics
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology
|
File:Iproniazid.png | |
| N'-propan-2-ylpyridine-4-carbohydrazide IUPAC name | |
| CAS number 54-92-2 | ATC code |
| PubChem 3748 | DrugBank [1] |
| Chemical formula | {{{chemical_formula}}} |
| Molecular weight | 179.219 |
| Bioavailability | ? |
| Metabolism | ? |
| Elimination half-life | ? |
| Excretion | ? |
| Pregnancy category | ? |
| Legal status | ? |
| Routes of administration | ? |
Iproniazid (iproniazid phosphate, marketed under the names Marsilid®, Iprozid®, Ipronid®, Rivivol®, Propilniazida®) is a monamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant. It was originally intended to treat tuberculosis when it was discovered that patients given iproniazid became "inappropriately happy," subsequently with further research iproniazid was marketed specifically for depression in 1958. It was later replaced by less hepatotoxic drugs.
[edit] See also
- Amine oxidase inhibitors
- Antidepressant drugs
- Antihypertensicve drugs
- Antitubercular drugs
- Monoamine oxidase inhibitors
| This page uses content from the English-language version of Wikipedia. The original article was at Iproniazid. The list of authors can be seen in the page history. As with Psychology Wiki, the text of Wikipedia is available under the GNU Free Documentation License. |
